(SURI) Simplify Propel - Ratings and Ratios

The Simplify Propel Opportunities ETF (NYSE ARCA:SURI) is an actively managed exchange-traded fund that focuses on the biotechnology, pharmaceuticals, healthcare technology, and life sciences sectors. The Sub-Adviser allocates more than 25% of the funds net assets to these industries, targeting companies involved in drug discovery, medical devices, digital health platforms, and diagnostic tools. The fund employs an opportunistic multi-asset strategy, diversifying its portfolio across various security types, including common stocks, preferred stocks, convertible bonds, structured notes, and corporate bonds. Additionally, it invests in ETFs that align with its core sectors. As a non-diversified fund, it can take concentrated positions in select securities, allowing for targeted exposure to high-conviction opportunities.

From a technical perspective, SURI is currently trading below its short-term and medium-term moving averages, with a last price of 16.54 compared to its SMA 20 of 17.21 and SMA 50 of 16.70. This indicates potential near-term weakness. However, its SMA 200 of 20.15 suggests longer-term downside momentum. The average trading volume of 1,774 shares over the past 20 days reflects relatively low liquidity, which may impact execution efficiency. The ATR of 0.44 highlights moderate volatility. On the fundamental side, the funds assets under management (AUM) of $78.12 million indicate a manageable size, allowing for flexibility in portfolio adjustments. Over the next three months, if the healthcare sector experiences a rebound driven by positive clinical trial outcomes or regulatory approvals, SURI could see a recovery, especially if its holdings in biotechnology and pharmaceuticals benefit from such developments. Conversely, broader market volatility or sector-specific headwinds could weigh on performance. The funds multi-asset approach may help mitigate risks, but its non-diversified nature could amplify both upside and downside movements.